Montreal, Quebec--(Newsfile Corp. - October 6, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug delivery technologies, is pleased to announce its participation at CPHI Worldwide 2025, taking place in Frankfurt, Germany from October 28-30, 2025.At this premier gathering and global trade fair of pharmaceutical leaders, Defence looks forward to engaging with potential partners across the biopharma value cha ...

Core Insights - Defence Therapeutics Inc. has appointed Dr. Amie Phinney to its Board of Directors, effective immediately, to enhance governance and long-term value creation as the company advances its drug-delivery platform [1][2][3] Group 1: Leadership Changes - Dr. Phinney previously served as a Strategy and Business Advisor and will now play a crucial role on the Board, contributing to strategic priorities and governance [2][3] - The CEO of Defence Therapeutics, Sébastien Plouffe, emphasized Dr. Phinney's significant impact on the company's strategic direction and her valuable experience in global pharma and biotech [3] Group 2: Incentives and Compensation - The company has granted Dr. Phinney 100,000 incentive stock options, which are vested immediately and exercisable at a price of $0.75 per share for three years [4] Group 3: Company Overview - Defence Therapeutics is a clinical-stage biotechnology company focused on developing next-generation antibody-drug conjugates (ADCs) using its proprietary ACCUM® technology, which allows for precision delivery to target cells, enhancing efficacy against cancer [5]

Group 1 - Defence Therapeutics Inc. has successfully closed a non-brokered private placement of debenture units, raising a total of $2,000,000 [1][5] - Each debenture unit consists of one $1,000 principal amount 8.0% convertible debenture and 1,666 common share purchase warrants [1][2] - The debentures have a maturity date of September 15, 2027, and are convertible into common shares at a price of $0.60 per share [2][3] Group 2 - The company paid a total of $160,000 in cash finder's fees and issued 266,667 finder's warrants, which are also exercisable at $0.75 per share [4] - The net proceeds from the offering will be used to advance the company's science programs and for general working capital [5] - All securities issued are subject to a statutory hold period of four months plus a day from their date of issue [5] Group 3 - Defence Therapeutics is a clinical-stage biotechnology company focused on developing next-generation antibody-drug conjugates (ADCs) using its proprietary ACCUM® technology [7]

Company Overview - Defence Therapeutics Inc. is a clinical-stage biotechnology company focused on drug delivery technologies, particularly in developing next-generation antibody-drug conjugates (ADCs) using its proprietary ACCUM® technology, which enhances the precision delivery of ADCs to target cells, thereby increasing efficacy against cancer [5]. Leadership Appointment - Dr. Amie Phinney has been appointed as the Strategy & Business Advisor to guide Defence Therapeutics in its next phase of growth, effective immediately [1]. - Dr. Phinney brings over 20 years of experience in life sciences commercialization, having held significant roles in pharmaceutical R&D and biotech innovation at companies like Abbott and AbbVie [2][3]. Strategic Vision - The company is at a pivotal point, with its scientific advancements opening new transformative opportunities. Dr. Phinney's expertise in both scientific and strategic leadership is expected to help the company capture this momentum for sustainable growth [4]. - Dr. Phinney expressed enthusiasm about joining Defence Therapeutics, highlighting the potential of the company's science to transform the field of antibody-delivered therapeutics and her commitment to building a roadmap for innovation [4].

Core Viewpoint - Defence Therapeutics Inc. is conducting a non-brokered private placement of debenture units to raise up to $1,200,000, aimed at enhancing its drug delivery technologies [1][2]. Financing Details - The offering consists of debenture units priced at $1,000 each, with a total gross proceeds target of $1,200,000 [1]. - Each unit includes one $1,000 principal amount of an 8.0% convertible debenture and 1,666 common share purchase warrants [1][2]. - The debentures will bear an interest rate of 8.0% per annum and will mature two years from the issue date [2]. - The principal amount of each debenture is convertible into common shares at a conversion price of $0.60 per share [2]. - Accrued interest can be paid annually in shares at the conversion price or in cash at the company's discretion [2]. Warrant Details - Each warrant allows the holder to acquire one common share at an exercise price of $0.75 for a period of two years from the issue date [3]. Regulatory and Compliance Information - All securities issued will be subject to a statutory hold period of four months and one day following the closing date [4]. - The completion of the offering is contingent upon receiving all necessary regulatory approvals [4]. - The company may pay a finder's fee to eligible arm's length finders in accordance with Canadian Securities Exchange policies [4]. Company Overview - Defence Therapeutics is a clinical-stage biotechnology company focused on developing next-generation antibody-drug conjugates (ADCs) using its proprietary ACCUM® technology, which enhances the precision delivery of ADCs to target cells, thereby increasing efficacy against cancer [6].

Core Insights - Defence Therapeutics Inc. has appointed Dr. Elias Theodorou as Chief Operating Officer, effective April 2025, to enhance its management team and accelerate development programs [2][3] - Dr. Theodorou brings over 25 years of experience in cancer research and innovative drug delivery systems, which aligns with Defence's mission to advance its proprietary Accum® technology [3][4] - The company has granted Dr. Theodorou 350,000 incentive stock options, with 100,000 vesting immediately and the remainder vesting in one year, exercisable at $1.07 per share for ten years [3] Company Overview - Defence Therapeutics is a clinical-stage biotechnology company focused on developing radio-immuno-conjugate and antibody-drug conjugate (ADC) products using its proprietary platform [4] - The core technology, Accum®, enables precision delivery of therapeutic agents to target cells, aiming to improve efficacy against cancer and infectious diseases [5]